secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001193125-24-140533
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa prices $100M public offering of common stock and pre-funded warrants
-------------------------------------------------------------------------------

- Priced 10.6M shares at $4.70/share and pre-funded warrants for 10.6M shares at $4.6999/warrant; gross proceeds $100M.
- Net proceeds ~$96.7M; expected close May 20, 2024; led by Dimension and a life-sciences institutional investor.
- Funds to advance MRT-6160, MRT-8102 clinical programs and QuEEN platform; cash runway into H1 2027.
- Underwriters: TD Cowen and Wedbush PacGrow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312524140533/0001193125-24-140533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312524140533/d813909d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-140533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer